CDCP2 (CUB domain containing protein 2) is a gene whose protein product appears to be involved in multiple pathological processes, though its primary molecular function remains incompletely characterized. CDCP2 contains CUB domains, which are conserved protein interaction modules found in extracellular proteins. The gene has been identified in association with several disease states through differential methylation and expression profiling studies. In cardiovascular disease, CDCP2 was identified among genes with differentially methylated CpG sites in ascending aortic tissue from patients with aortic aneurysm and atherosclerosis 1. Its protein product is implicated in biological processes relevant to both aortic dissection and atherosclerosis across arterial regions 1. In diabetic cardiomyopathy, a long noncoding RNA (lnc-CDCP2-1) was identified as significantly linked to fibrosis-associated mRNAs and myocardial fibrosis development 2. CDCP2 expression also demonstrated prognostic value in temporal lobe epilepsy, with relative down-regulation of CDCP2 associated with seizure-free outcomes following anterior temporal lobectomy and amygdalohippocampectomy 3. Additionally, differential methylation of CDCP2 was detected in epithelial ovarian cancer patients with primary platinum resistance, suggesting potential epigenetic involvement in chemotherapy response 4. While CDCP2 has not been confirmed as a Parkinson disease risk gene 5, these findings collectively suggest CDCP2 involvement in vascular, cardiac, neurological, and oncological pathologies, primarily identified through epigenetic rather than functional studies.